Efficacy of a killed vaccine for the control of paratuberculosis in Australian sheep flocks.
A field trial was undertaken from 1999 until 2004 to determine the efficacy of a killed M. a. paratuberculosis vaccine, Gudair, for the control of ovine Johne's disease (OJD) in merino sheep run under Australian pastoral conditions. On each of three farms experiencing significant OJD losses (5-15% per annum), 200 merino lambs (age 1-4 months) were vaccinated, and 200 lambs were left unvaccinated. Animal assessments and sample collections were conducted twice yearly until 4 or 5 years of age. The impact of vaccination on mortality rate, faecal shedding of M. a. paratuberculosis (by pooled and individual faecal culture), liveweight, wool productivity, vaccine injection site lesions and cellular (BOVIGAM) and humoral (PARACHEK) immunity was examined. Vaccination stimulated cell-mediated and humoral immune responses, reduced mortalities due to OJD by 90% and delayed faecal shedding for the first year post-vaccination. Thereafter, the prevalence of shedders among vaccinates was reduced by 90%. The numbers of M. a. paratuberculosis excreted by the vaccinated groups were also reduced by at least 90% at most sampling times. However, high levels of excretion by vaccinates occurred on some occasions, and although only 7 of 600 vaccinates died from OJD, all 7 had multibacillary lesions. Thus there remains a risk that some vaccinated sheep will transfer the disease. Small reductions in liveweight were found in vaccinated lambs in the first year, but there was little effect on wool production. Vaccine injection site lesions were detected in almost 50% of sheep after 2 months, and these persisted for at least 4 years in 20-25% of vaccinates. Data from this trial enabled the registration of Gudair in Australia in 2002 and underpins the pivotal role of vaccination in the current management of OJD.
Reddacliff
L
L
NSW Department of Primary Industries, PMB 8, Camden, NSW 2570, Australia. leslie.reddacliff@dpi.nsw.gov.au
Eppleston
J
J
Windsor
P
P
Whittington
R
R
Jones
S
S
D000818:Animals; D000831:Animals, Newborn; D000917:Antibody Formation; D001315:Australia / Q000453:epidemiology; D001428:Bacterial Vaccines / Q000276:immunology*; D005243:Feces / Q000382:microbiology; D005260:Female; D007111:Immunity, Cellular; D016927:Mycobacterium avium subsp. paratuberculosis / Q000276:immunology*; D010283:Paratuberculosis / Q000453:epidemiology / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D011897:Random Allocation; D012756:Sheep / Q000254:growth & development; D012757:Sheep Diseases / Q000453:epidemiology / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D014611:Vaccination / Q000592:standards / Q000662:veterinary*; D015164:Vaccines, Inactivated / Q000276:immunology; D015430:Weight Gain; D014935:Wool
D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated